Background/Objectives Coronavirus disease 2019 (COVID-19) is associated with a hypercoagulable state and increased thrombotic risk in infected individuals. Several complex and varied coagulation abnormalities were proposed for this association¹. Acetylsalicylic acid(ASA, aspirin) is known to have inflammatory, antithrombotic properties and its use was reported as having potency to reduce RNA synthesis and replication of some types of coronaviruses including human coronavirus-299E (CoV-229E) and Middle East Respiratory Syndrome (MERS)-CoV ^2,3. We hypothesized that chronic low dose aspirin use may decrease COVID-19 mortality relative to ASA non-users.

中文翻译：

---

VA 社区生活中心疗养院 COVID-19 居民的死亡率和阿司匹林使用关联

背景/目标2019 年冠状病毒病 (COVID-19) 与感染个体的高凝状态和血栓形成风险增加有关。对于这种关联，提出了几种复杂且多样的凝血异常¹。已知乙酰水杨酸（ASA，阿司匹林）具有抗炎、抗血栓形成的特性，据报道其用途可减少某些类型冠状病毒的 RNA 合成和复制，包括人类冠状病毒-299E (CoV-229E) 和中东呼吸综合征 ( MERS)-CoV ^2,3。我们假设长期使用低剂量阿司匹林可能会相对于非 ASA 使用者降低 COVID-19 死亡率。